#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=7. Involvement of the Apelin System in the Pathogenesis of Liver Fibrosis
1-1	0-2	7.	_	_	_	_
1-2	3-14	Involvement	abstract[1]	new[1]	_	_
1-3	15-17	of	abstract[1]	new[1]	_	_
1-4	18-21	the	abstract[1]|abstract[3]	new[1]|new[3]	coref	2-1[8_3]
1-5	22-28	Apelin	abstract[1]|substance|abstract[3]	new[1]|new|new[3]	coref	2-2
1-6	29-35	System	abstract[1]|abstract[3]	new[1]|new[3]	_	_
1-7	36-38	in	abstract[1]|abstract[3]	new[1]|new[3]	_	_
1-8	39-42	the	abstract[1]|abstract[3]|abstract[4]	new[1]|new[3]|new[4]	_	_
1-9	43-55	Pathogenesis	abstract[1]|abstract[3]|abstract[4]	new[1]|new[3]|new[4]	_	_
1-10	56-58	of	abstract[1]|abstract[3]|abstract[4]	new[1]|new[3]|new[4]	_	_
1-11	59-64	Liver	abstract[1]|abstract[3]|abstract[4]|object|abstract[6]	new[1]|new[3]|new[4]|new|new[6]	coref	5-16
1-12	65-73	Fibrosis	abstract[1]|abstract[3]|abstract[4]|abstract[6]	new[1]|new[3]|new[4]|new[6]	_	_

#Text=The apelin system has certain therapeutic abilities , but it may also play a role in disease depending on the cellular and molecular milieu .
2-1	74-77	The	abstract[8]	giv[8]	ana	2-10[0_8]
2-2	78-84	apelin	substance|abstract[8]	giv|giv[8]	coref	3-10
2-3	85-91	system	abstract[8]	giv[8]	_	_
2-4	92-95	has	_	_	_	_
2-5	96-103	certain	abstract[9]	new[9]	_	_
2-6	104-115	therapeutic	abstract[9]	new[9]	_	_
2-7	116-125	abilities	abstract[9]	new[9]	_	_
2-8	126-127	,	_	_	_	_
2-9	128-131	but	_	_	_	_
2-10	132-134	it	abstract	giv	coref	5-9[29_0]
2-11	135-138	may	_	_	_	_
2-12	139-143	also	_	_	_	_
2-13	144-148	play	_	_	_	_
2-14	149-150	a	abstract[11]	new[11]	coref	5-7[27_11]
2-15	151-155	role	abstract[11]	new[11]	_	_
2-16	156-158	in	abstract[11]	new[11]	_	_
2-17	159-166	disease	abstract[11]|abstract	new[11]|new	coref	5-16[31_0]
2-18	167-176	depending	_	_	_	_
2-19	177-179	on	_	_	_	_
2-20	180-183	the	abstract[13]	new[13]	_	_
2-21	184-192	cellular	abstract[13]	new[13]	_	_
2-22	193-196	and	abstract[13]	new[13]	_	_
2-23	197-206	molecular	abstract[13]	new[13]	_	_
2-24	207-213	milieu	abstract[13]	new[13]	_	_
2-25	214-215	.	_	_	_	_

#Text=A clear example of this is the role of apelin in tissue fibrosis .
3-1	216-217	A	abstract[14]	new[14]	coref	3-7[15_14]
3-2	218-223	clear	abstract[14]	new[14]	_	_
3-3	224-231	example	abstract[14]	new[14]	_	_
3-4	232-234	of	abstract[14]	new[14]	_	_
3-5	235-239	this	abstract[14]	new[14]	_	_
3-6	240-242	is	_	_	_	_
3-7	243-246	the	abstract[15]	giv[15]	_	_
3-8	247-251	role	abstract[15]	giv[15]	_	_
3-9	252-254	of	abstract[15]	giv[15]	_	_
3-10	255-261	apelin	abstract[15]|substance	giv[15]|giv	coref	4-1
3-11	262-264	in	abstract[15]	giv[15]	_	_
3-12	265-271	tissue	abstract[15]|substance|object[18]	giv[15]|new|new[18]	coref	4-10[23_18]
3-13	272-280	fibrosis	abstract[15]|object[18]	giv[15]|new[18]	_	_
3-14	281-282	.	_	_	_	_

#Text=Apelin displays anti-fibrotic actions counteracting AII in models of cardiac fibrosis and renal fibrosis .
4-1	283-289	Apelin	substance	giv	coref	5-10
4-2	290-298	displays	_	_	_	_
4-3	299-312	anti-fibrotic	abstract[20]	new[20]	_	_
4-4	313-320	actions	abstract[20]	new[20]	_	_
4-5	321-334	counteracting	abstract[20]	new[20]	_	_
4-6	335-338	AII	abstract[20]|abstract	new[20]|new	coref	6-19
4-7	339-341	in	abstract[20]	new[20]	_	_
4-8	342-348	models	abstract[20]|abstract[22]	new[20]|new[22]	_	_
4-9	349-351	of	abstract[20]|abstract[22]	new[20]|new[22]	_	_
4-10	352-359	cardiac	abstract[20]|abstract[22]|object[23]	new[20]|new[22]|giv[23]	coref	4-13[24_23]
4-11	360-368	fibrosis	abstract[20]|abstract[22]|object[23]	new[20]|new[22]|giv[23]	_	_
4-12	369-372	and	abstract[20]|abstract[22]	new[20]|new[22]	_	_
4-13	373-378	renal	abstract[20]|abstract[22]|object[24]	new[20]|new[22]|giv[24]	coref	6-29[41_24]
4-14	379-387	fibrosis	abstract[20]|abstract[22]|object[24]	new[20]|new[22]|giv[24]	_	_
4-15	388-389	.	_	_	_	_

#Text=In contrast , the scenario and role of the apelin system are completely different in liver disease .
5-1	390-392	In	_	_	_	_
5-2	393-401	contrast	_	_	_	_
5-3	402-403	,	_	_	_	_
5-4	404-407	the	abstract[25]|abstract[26]	new[25]|new[26]	ana	6-12[34_26]
5-5	408-416	scenario	abstract[25]|abstract[26]	new[25]|new[26]	_	_
5-6	417-420	and	abstract[26]	new[26]	_	_
5-7	421-425	role	abstract[26]|abstract[27]	new[26]|giv[27]	_	_
5-8	426-428	of	abstract[26]|abstract[27]	new[26]|giv[27]	_	_
5-9	429-432	the	abstract[26]|abstract[27]|abstract[29]	new[26]|giv[27]|giv[29]	_	_
5-10	433-439	apelin	abstract[26]|abstract[27]|substance|abstract[29]	new[26]|giv[27]|giv|giv[29]	coref	6-1
5-11	440-446	system	abstract[26]|abstract[27]|abstract[29]	new[26]|giv[27]|giv[29]	_	_
5-12	447-450	are	_	_	_	_
5-13	451-461	completely	_	_	_	_
5-14	462-471	different	_	_	_	_
5-15	472-474	in	_	_	_	_
5-16	475-480	liver	object|abstract[31]	giv|giv[31]	coref|coref	6-29|11-27[91_31]
5-17	481-488	disease	abstract[31]	giv[31]	_	_
5-18	489-490	.	_	_	_	_

#Text=Apelin is a hepatic pro-fibrotic agent , in part by mediating some of the fibrogenic effects triggered by AII and ET-1 in the activation of HSC occurring in liver fibrosis .
6-1	491-497	Apelin	substance	giv	coref	6-3[33_0]
6-2	498-500	is	_	_	_	_
6-3	501-502	a	substance[33]	giv[33]	coref	7-24[0_33]
6-4	503-510	hepatic	substance[33]	giv[33]	_	_
6-5	511-523	pro-fibrotic	substance[33]	giv[33]	_	_
6-6	524-529	agent	substance[33]	giv[33]	_	_
6-7	530-531	,	substance[33]	giv[33]	_	_
6-8	532-534	in	substance[33]	giv[33]	_	_
6-9	535-539	part	substance[33]	giv[33]	_	_
6-10	540-542	by	substance[33]	giv[33]	_	_
6-11	543-552	mediating	substance[33]	giv[33]	_	_
6-12	553-557	some	substance[33]|abstract[34]	giv[33]|giv[34]	_	_
6-13	558-560	of	substance[33]|abstract[34]	giv[33]|giv[34]	_	_
6-14	561-564	the	substance[33]|abstract[34]|abstract[35]	giv[33]|giv[34]|new[35]	_	_
6-15	565-575	fibrogenic	substance[33]|abstract[34]|abstract[35]	giv[33]|giv[34]|new[35]	_	_
6-16	576-583	effects	substance[33]|abstract[34]|abstract[35]	giv[33]|giv[34]|new[35]	_	_
6-17	584-593	triggered	substance[33]|abstract[34]|abstract[35]	giv[33]|giv[34]|new[35]	_	_
6-18	594-596	by	substance[33]|abstract[34]|abstract[35]	giv[33]|giv[34]|new[35]	_	_
6-19	597-600	AII	substance[33]|abstract[34]|abstract[35]|abstract	giv[33]|giv[34]|new[35]|giv	coref	27-10
6-20	601-604	and	substance[33]|abstract[34]|abstract[35]	giv[33]|giv[34]|new[35]	_	_
6-21	605-609	ET-1	substance[33]|abstract[34]|abstract[35]|abstract	giv[33]|giv[34]|new[35]|new	_	_
6-22	610-612	in	substance[33]|abstract[34]|abstract[35]	giv[33]|giv[34]|new[35]	_	_
6-23	613-616	the	substance[33]|abstract[34]|abstract[35]|event[38]	giv[33]|giv[34]|new[35]|new[38]	coref	10-17[81_38]
6-24	617-627	activation	substance[33]|abstract[34]|abstract[35]|event[38]	giv[33]|giv[34]|new[35]|new[38]	_	_
6-25	628-630	of	substance[33]|abstract[34]|abstract[35]|event[38]	giv[33]|giv[34]|new[35]|new[38]	_	_
6-26	631-634	HSC	substance[33]|abstract[34]|abstract[35]|event[38]|abstract[39]	giv[33]|giv[34]|new[35]|new[38]|new[39]	coref	9-19[0_39]
6-27	635-644	occurring	substance[33]|abstract[34]|abstract[35]|event[38]|abstract[39]	giv[33]|giv[34]|new[35]|new[38]|new[39]	_	_
6-28	645-647	in	substance[33]|abstract[34]|abstract[35]|event[38]|abstract[39]	giv[33]|giv[34]|new[35]|new[38]|new[39]	_	_
6-29	648-653	liver	substance[33]|abstract[34]|abstract[35]|event[38]|abstract[39]|object|object[41]	giv[33]|giv[34]|new[35]|new[38]|new[39]|giv|giv[41]	coref|coref	7-11|8-13[58_41]
6-30	654-662	fibrosis	substance[33]|abstract[34]|abstract[35]|event[38]|abstract[39]|object[41]	giv[33]|giv[34]|new[35]|new[38]|new[39]|giv[41]	_	_
6-31	663-664	.	_	_	_	_

#Text=These outcomes highlight the intriguing difference between myofibroblastic-cell types in liver compared to myofibroblasts in heart , kidney , or skin in which apelin acts by decreasing myofibroblast accumulation and activity .
7-1	665-670	These	abstract[42]	new[42]	_	_
7-2	671-679	outcomes	abstract[42]	new[42]	_	_
7-3	680-689	highlight	_	_	_	_
7-4	690-693	the	abstract[43]	new[43]	_	_
7-5	694-704	intriguing	abstract[43]	new[43]	_	_
7-6	705-715	difference	abstract[43]	new[43]	_	_
7-7	716-723	between	abstract[43]	new[43]	_	_
7-8	724-744	myofibroblastic-cell	abstract[43]|abstract[44]	new[43]|new[44]	_	_
7-9	745-750	types	abstract[43]|abstract[44]	new[43]|new[44]	_	_
7-10	751-753	in	abstract[43]|abstract[44]	new[43]|new[44]	_	_
7-11	754-759	liver	abstract[43]|abstract[44]|object	new[43]|new[44]|giv	coref	8-13
7-12	760-768	compared	abstract[43]	new[43]	_	_
7-13	769-771	to	abstract[43]	new[43]	_	_
7-14	772-786	myofibroblasts	abstract[43]|animal[46]	new[43]|new[46]	_	_
7-15	787-789	in	abstract[43]|animal[46]	new[43]|new[46]	_	_
7-16	790-795	heart	abstract[43]|animal[46]|object	new[43]|new[46]|new	_	_
7-17	796-797	,	abstract[43]|animal[46]	new[43]|new[46]	_	_
7-18	798-804	kidney	abstract[43]|animal[46]|object	new[43]|new[46]|new	_	_
7-19	805-806	,	abstract[43]|animal[46]	new[43]|new[46]	_	_
7-20	807-809	or	abstract[43]|animal[46]	new[43]|new[46]	_	_
7-21	810-814	skin	abstract[43]|animal[46]|object[49]	new[43]|new[46]|new[49]	_	_
7-22	815-817	in	abstract[43]|animal[46]|object[49]	new[43]|new[46]|new[49]	_	_
7-23	818-823	which	abstract[43]|animal[46]|object[49]	new[43]|new[46]|new[49]	_	_
7-24	824-830	apelin	abstract[43]|animal[46]|object[49]|substance	new[43]|new[46]|new[49]|giv	coref	8-4
7-25	831-835	acts	abstract[43]|animal[46]|object[49]	new[43]|new[46]|new[49]	_	_
7-26	836-838	by	_	_	_	_
7-27	839-849	decreasing	_	_	_	_
7-28	850-863	myofibroblast	person|abstract[52]	new|new[52]	_	_
7-29	864-876	accumulation	abstract[52]	new[52]	_	_
7-30	877-880	and	_	_	_	_
7-31	881-889	activity	abstract	new	_	_
7-32	890-891	.	_	_	_	_

#Text=In vitro , apelin has also demonstrated a significant potential to promote liver fibrosis .
8-1	892-894	In	_	_	_	_
8-2	895-900	vitro	organization	new	coref	9-16
8-3	901-902	,	_	_	_	_
8-4	903-909	apelin	substance	giv	coref	11-3
8-5	910-913	has	_	_	_	_
8-6	914-918	also	_	_	_	_
8-7	919-931	demonstrated	_	_	_	_
8-8	932-933	a	abstract[56]	new[56]	ana	9-1[0_56]
8-9	934-945	significant	abstract[56]	new[56]	_	_
8-10	946-955	potential	abstract[56]	new[56]	_	_
8-11	956-958	to	abstract[56]	new[56]	_	_
8-12	959-966	promote	abstract[56]	new[56]	_	_
8-13	967-972	liver	abstract[56]|object|object[58]	new[56]|giv|giv[58]	coref|coref	11-24|11-24[89_58]
8-14	973-981	fibrosis	abstract[56]|object[58]	new[56]|giv[58]	_	_
8-15	982-983	.	_	_	_	_

#Text=It acts directly on LX-2 cells ( a cell line used as a reliable in vitro model of HSC ) through Erk signalling , stimulating cell survival and the synthesis of PDGF-β receptor and collagen-I in these cells .
9-1	984-986	It	abstract	giv	_	_
9-2	987-991	acts	_	_	_	_
9-3	992-1000	directly	_	_	_	_
9-4	1001-1003	on	_	_	_	_
9-5	1004-1008	LX-2	substance|animal[61]	new|new[61]	coref|coref	9-37[75_61]|18-48
9-6	1009-1014	cells	animal[61]	new[61]	_	_
9-7	1015-1016	(	_	_	_	_
9-8	1017-1018	a	object[63]	new[63]	_	_
9-9	1019-1023	cell	object|object[63]	new|new[63]	coref	9-26
9-10	1024-1028	line	object[63]	new[63]	_	_
9-11	1029-1033	used	object[63]	new[63]	_	_
9-12	1034-1036	as	object[63]	new[63]	_	_
9-13	1037-1038	a	object[63]|abstract[65]	new[63]|new[65]	_	_
9-14	1039-1047	reliable	object[63]|abstract[65]	new[63]|new[65]	_	_
9-15	1048-1050	in	object[63]|abstract[65]	new[63]|new[65]	_	_
9-16	1051-1056	vitro	object[63]|organization|abstract[65]	new[63]|giv|new[65]	coref	26-4
9-17	1057-1062	model	object[63]|abstract[65]	new[63]|new[65]	_	_
9-18	1063-1065	of	object[63]|abstract[65]	new[63]|new[65]	_	_
9-19	1066-1069	HSC	object[63]|abstract[65]|abstract	new[63]|new[65]|giv	coref	10-17
9-20	1070-1071	)	_	_	_	_
9-21	1072-1079	through	_	_	_	_
9-22	1080-1083	Erk	person|abstract[68]	new|new[68]	coref	16-20[0_68]
9-23	1084-1094	signalling	abstract[68]	new[68]	_	_
9-24	1095-1096	,	_	_	_	_
9-25	1097-1108	stimulating	_	_	_	_
9-26	1109-1113	cell	object|event[70]	giv|new[70]	_	_
9-27	1114-1122	survival	event[70]	new[70]	_	_
9-28	1123-1126	and	_	_	_	_
9-29	1127-1130	the	event[71]	new[71]	_	_
9-30	1131-1140	synthesis	event[71]	new[71]	_	_
9-31	1141-1143	of	event[71]	new[71]	_	_
9-32	1144-1150	PDGF-β	event[71]|abstract|substance[73]	new[71]|new|new[73]	coref	10-4
9-33	1151-1159	receptor	event[71]|substance[73]	new[71]|new[73]	_	_
9-34	1160-1163	and	event[71]	new[71]	_	_
9-35	1164-1174	collagen-I	event[71]|substance	new[71]|new	_	_
9-36	1175-1177	in	event[71]	new[71]	_	_
9-37	1178-1183	these	event[71]|animal[75]	new[71]|giv[75]	coref	18-48[141_75]
9-38	1184-1189	cells	event[71]|animal[75]	new[71]|giv[75]	_	_
9-39	1190-1191	.	_	_	_	_

#Text=In turn , PDGF-β and LPS can stimulate the expression of APJ , expanding and perpetuating HSC activation .
10-1	1192-1194	In	_	_	_	_
10-2	1195-1199	turn	_	_	_	_
10-3	1200-1201	,	_	_	_	_
10-4	1202-1208	PDGF-β	abstract	giv	coref	28-12
10-5	1209-1212	and	_	_	_	_
10-6	1213-1216	LPS	abstract	new	_	_
10-7	1217-1220	can	_	_	_	_
10-8	1221-1230	stimulate	_	_	_	_
10-9	1231-1234	the	abstract[78]	new[78]	coref	27-13[219_78]
10-10	1235-1245	expression	abstract[78]	new[78]	_	_
10-11	1246-1248	of	abstract[78]	new[78]	_	_
10-12	1249-1252	APJ	abstract[78]|abstract	new[78]|new	coref	14-12
10-13	1253-1254	,	_	_	_	_
10-14	1255-1264	expanding	_	_	_	_
10-15	1265-1268	and	_	_	_	_
10-16	1269-1281	perpetuating	_	_	_	_
10-17	1282-1285	HSC	abstract|event[81]	giv|giv[81]	coref	11-10
10-18	1286-1296	activation	event[81]	giv[81]	_	_
10-19	1297-1298	.	_	_	_	_

#Text=Therefore , apelin may , in theory , induce HSC to a pro-fibrogenic profile and prolong its stimulation autocrinally during all stages of liver fibrosis in chronic liver disease (
11-1	1299-1308	Therefore	_	_	_	_
11-2	1309-1310	,	_	_	_	_
11-3	1311-1317	apelin	substance	giv	ana	11-17
11-4	1318-1321	may	_	_	_	_
11-5	1322-1323	,	_	_	_	_
11-6	1324-1326	in	_	_	_	_
11-7	1327-1333	theory	_	_	_	_
11-8	1334-1335	,	_	_	_	_
11-9	1336-1342	induce	_	_	_	_
11-10	1343-1346	HSC	abstract	giv	coref	19-8
11-11	1347-1349	to	_	_	_	_
11-12	1350-1351	a	abstract[84]	new[84]	_	_
11-13	1352-1366	pro-fibrogenic	abstract[84]	new[84]	_	_
11-14	1367-1374	profile	abstract[84]	new[84]	_	_
11-15	1375-1378	and	_	_	_	_
11-16	1379-1386	prolong	_	_	_	_
11-17	1387-1390	its	substance|abstract[86]	giv|new[86]	coref	16-5
11-18	1391-1402	stimulation	abstract[86]	new[86]	_	_
11-19	1403-1415	autocrinally	_	_	_	_
11-20	1416-1422	during	_	_	_	_
11-21	1423-1426	all	abstract[87]	new[87]	_	_
11-22	1427-1433	stages	abstract[87]	new[87]	_	_
11-23	1434-1436	of	abstract[87]	new[87]	_	_
11-24	1437-1442	liver	abstract[87]|object|object[89]	new[87]|giv|giv[89]	coref|coref	11-28|14-21[0_89]
11-25	1443-1451	fibrosis	abstract[87]|object[89]	new[87]|giv[89]	_	_
11-26	1452-1454	in	abstract[87]|object[89]	new[87]|giv[89]	_	_
11-27	1455-1462	chronic	abstract[87]|object[89]|abstract[91]	new[87]|giv[89]|giv[91]	coref	18-43[139_91]
11-28	1463-1468	liver	abstract[87]|object[89]|object|abstract[91]	new[87]|giv[89]|giv|giv[91]	coref	18-44
11-29	1469-1476	disease	abstract[87]|object[89]|abstract[91]	new[87]|giv[89]|giv[91]	_	_
11-30	1477-1478	(	_	_	_	_

#Text=Figure 6
12-1	1479-1485	Figure	abstract[92]	new[92]	_	_
12-2	1486-1487	6	abstract[92]	new[92]	_	_

#Text=) .
13-1	1488-1489	)	_	_	_	_
13-2	1490-1491	.	_	_	_	_

#Text=In fact , some data have revealed that the inhibition of APJ using F13A ( an APJ antagonist ) prevents fibrosis progression in rats under a non-discontinued fibrosis induction program using CCl4 .
14-1	1492-1494	In	_	_	_	_
14-2	1495-1499	fact	_	_	_	_
14-3	1500-1501	,	_	_	_	_
14-4	1502-1506	some	abstract[93]	new[93]	coref	29-3[236_93]
14-5	1507-1511	data	abstract[93]	new[93]	_	_
14-6	1512-1516	have	_	_	_	_
14-7	1517-1525	revealed	_	_	_	_
14-8	1526-1530	that	_	_	_	_
14-9	1531-1534	the	event[94]	new[94]	_	_
14-10	1535-1545	inhibition	event[94]	new[94]	_	_
14-11	1546-1548	of	event[94]	new[94]	_	_
14-12	1549-1552	APJ	event[94]|abstract	new[94]|giv	coref	14-17
14-13	1553-1558	using	event[94]	new[94]	_	_
14-14	1559-1563	F13A	event[94]|abstract	new[94]|new	_	_
14-15	1564-1565	(	_	_	_	_
14-16	1566-1568	an	substance[98]	new[98]	_	_
14-17	1569-1572	APJ	abstract|substance[98]	giv|new[98]	coref	16-15[114_0]
14-18	1573-1583	antagonist	substance[98]	new[98]	_	_
14-19	1584-1585	)	_	_	_	_
14-20	1586-1594	prevents	_	_	_	_
14-21	1595-1603	fibrosis	object|event[100]	giv|new[100]	coref	14-28
14-22	1604-1615	progression	event[100]	new[100]	_	_
14-23	1616-1618	in	_	_	_	_
14-24	1619-1623	rats	animal	new	coref	17-22[125_0]
14-25	1624-1629	under	_	_	_	_
14-26	1630-1631	a	abstract[104]	new[104]	_	_
14-27	1632-1648	non-discontinued	abstract[104]	new[104]	_	_
14-28	1649-1657	fibrosis	object|abstract[104]	giv|new[104]	coref	15-14
14-29	1658-1667	induction	abstract|abstract[104]	new|new[104]	_	_
14-30	1668-1675	program	abstract[104]	new[104]	_	_
14-31	1676-1681	using	abstract[104]	new[104]	_	_
14-32	1682-1686	CCl4	abstract[104]|abstract	new[104]|new	coref	20-22[156_0]
14-33	1687-1688	.	_	_	_	_

#Text=Several investigations have uncovered the close and integrated relationship between pathological angiogenesis and fibrosis .
15-1	1689-1696	Several	abstract[106]	new[106]	_	_
15-2	1697-1711	investigations	abstract[106]	new[106]	_	_
15-3	1712-1716	have	_	_	_	_
15-4	1717-1726	uncovered	_	_	_	_
15-5	1727-1730	the	abstract[107]	new[107]	coref	18-2[126_107]
15-6	1731-1736	close	abstract[107]	new[107]	_	_
15-7	1737-1740	and	abstract[107]	new[107]	_	_
15-8	1741-1751	integrated	abstract[107]	new[107]	_	_
15-9	1752-1764	relationship	abstract[107]	new[107]	_	_
15-10	1765-1772	between	abstract[107]	new[107]	_	_
15-11	1773-1785	pathological	abstract[107]|abstract[108]|abstract[109]	new[107]|new[108]|new[109]	coref|coref	17-13[0_108]|20-13[152_109]
15-12	1786-1798	angiogenesis	abstract[107]|abstract[108]|abstract[109]	new[107]|new[108]|new[109]	_	_
15-13	1799-1802	and	abstract[107]|abstract[109]	new[107]|new[109]	_	_
15-14	1803-1811	fibrosis	abstract[107]|abstract[109]|object	new[107]|new[109]|giv	coref	17-20
15-15	1812-1813	.	_	_	_	_

#Text=As mentioned above , apelin is a powerful angiogenic agent through the activation of endothelial APJ and different downstream signalling pathways .
16-1	1814-1816	As	_	_	_	_
16-2	1817-1826	mentioned	substance[112]	giv[112]	coref|coref	16-2[112_0]|18-22[0_112]
16-3	1827-1832	above	substance[112]	giv[112]	_	_
16-4	1833-1834	,	substance[112]	giv[112]	_	_
16-5	1835-1841	apelin	substance|substance[112]	giv|giv[112]	_	_
16-6	1842-1844	is	substance[112]	giv[112]	_	_
16-7	1845-1846	a	substance[112]	giv[112]	_	_
16-8	1847-1855	powerful	substance[112]	giv[112]	_	_
16-9	1856-1866	angiogenic	substance[112]	giv[112]	_	_
16-10	1867-1872	agent	substance[112]	giv[112]	_	_
16-11	1873-1880	through	substance[112]	giv[112]	_	_
16-12	1881-1884	the	substance[112]|event[113]	giv[112]|new[113]	coref	18-19[130_113]
16-13	1885-1895	activation	substance[112]|event[113]	giv[112]|new[113]	_	_
16-14	1896-1898	of	substance[112]|event[113]	giv[112]|new[113]	_	_
16-15	1899-1910	endothelial	substance[112]|event[113]|abstract[114]	giv[112]|new[113]|giv[114]	coref	17-8[0_114]
16-16	1911-1914	APJ	substance[112]|event[113]|abstract[114]	giv[112]|new[113]|giv[114]	_	_
16-17	1915-1918	and	substance[112]|event[113]	giv[112]|new[113]	_	_
16-18	1919-1928	different	substance[112]|event[113]|abstract[116]	giv[112]|new[113]|new[116]	_	_
16-19	1929-1939	downstream	substance[112]|event[113]|abstract[116]	giv[112]|new[113]|new[116]	_	_
16-20	1940-1950	signalling	substance[112]|event[113]|abstract|abstract[116]	giv[112]|new[113]|giv|new[116]	_	_
16-21	1951-1959	pathways	substance[112]|event[113]|abstract[116]	giv[112]|new[113]|new[116]	_	_
16-22	1960-1961	.	_	_	_	_

#Text=Two reports have associated the inhibition of APJ with a reduction in angiogenesis and with a concomitant drop in fibrosis in CH and fibrotic rats .
17-1	1962-1965	Two	abstract[117]	new[117]	_	_
17-2	1966-1973	reports	abstract[117]	new[117]	_	_
17-3	1974-1978	have	_	_	_	_
17-4	1979-1989	associated	_	_	_	_
17-5	1990-1993	the	event[118]	new[118]	_	_
17-6	1994-2004	inhibition	event[118]	new[118]	_	_
17-7	2005-2007	of	event[118]	new[118]	_	_
17-8	2008-2011	APJ	event[118]|abstract	new[118]|giv	coref	18-19
17-9	2012-2016	with	_	_	_	_
17-10	2017-2018	a	event[120]	new[120]	_	_
17-11	2019-2028	reduction	event[120]	new[120]	_	_
17-12	2029-2031	in	event[120]	new[120]	_	_
17-13	2032-2044	angiogenesis	event[120]|abstract	new[120]|giv	coref	18-40[137_0]
17-14	2045-2048	and	_	_	_	_
17-15	2049-2053	with	_	_	_	_
17-16	2054-2055	a	object[122]	new[122]	_	_
17-17	2056-2067	concomitant	object[122]	new[122]	_	_
17-18	2068-2072	drop	object[122]	new[122]	_	_
17-19	2073-2075	in	object[122]	new[122]	_	_
17-20	2076-2084	fibrosis	object[122]|object	new[122]|giv	coref	20-16[154_0]
17-21	2085-2087	in	object[122]	new[122]	_	_
17-22	2088-2090	CH	object[122]|animal|animal[125]	new[122]|new|giv[125]	coref	30-23[257_125]
17-23	2091-2094	and	object[122]|animal[125]	new[122]|giv[125]	_	_
17-24	2095-2103	fibrotic	object[122]|animal[125]	new[122]|giv[125]	_	_
17-25	2104-2108	rats	object[122]|animal[125]	new[122]|giv[125]	_	_
17-26	2109-2110	.	_	_	_	_

#Text=Although a direct relationship was not established between the two phenomena , there are evidence pointing out that APJ activation by apelin stimulates the expression of a well-known pro-angiogenic factor , angiopoietin-1 ( from the angiopoietin family involved in pathological angiogenesis in chronic liver disease ) in LX-2 cells .
18-1	2111-2119	Although	_	_	_	_
18-2	2120-2121	a	abstract[126]	giv[126]	_	_
18-3	2122-2128	direct	abstract[126]	giv[126]	_	_
18-4	2129-2141	relationship	abstract[126]	giv[126]	_	_
18-5	2142-2145	was	_	_	_	_
18-6	2146-2149	not	_	_	_	_
18-7	2150-2161	established	_	_	_	_
18-8	2162-2169	between	_	_	_	_
18-9	2170-2173	the	abstract[127]	new[127]	coref	21-13[160_127]
18-10	2174-2177	two	abstract[127]	new[127]	_	_
18-11	2178-2187	phenomena	abstract[127]	new[127]	_	_
18-12	2188-2189	,	_	_	_	_
18-13	2190-2195	there	_	_	_	_
18-14	2196-2199	are	_	_	_	_
18-15	2200-2208	evidence	abstract[128]	new[128]	_	_
18-16	2209-2217	pointing	abstract[128]	new[128]	_	_
18-17	2218-2221	out	abstract[128]	new[128]	_	_
18-18	2222-2226	that	abstract[128]	new[128]	_	_
18-19	2227-2230	APJ	abstract[128]|abstract|event[130]	new[128]|giv|giv[130]	ana|coref	19-1[0_130]|26-8
18-20	2231-2241	activation	abstract[128]|event[130]	new[128]|giv[130]	_	_
18-21	2242-2244	by	abstract[128]|event[130]	new[128]|giv[130]	_	_
18-22	2245-2251	apelin	abstract[128]|event[130]|substance	new[128]|giv[130]|giv	coref	29-29
18-23	2252-2262	stimulates	abstract[128]	new[128]	_	_
18-24	2263-2266	the	abstract[128]|abstract[132]	new[128]|new[132]	_	_
18-25	2267-2277	expression	abstract[128]|abstract[132]	new[128]|new[132]	_	_
18-26	2278-2280	of	abstract[128]|abstract[132]	new[128]|new[132]	_	_
18-27	2281-2282	a	abstract[128]|abstract[132]|abstract[133]	new[128]|new[132]|new[133]	appos	18-32[0_133]
18-28	2283-2293	well-known	abstract[128]|abstract[132]|abstract[133]	new[128]|new[132]|new[133]	_	_
18-29	2294-2308	pro-angiogenic	abstract[128]|abstract[132]|abstract[133]	new[128]|new[132]|new[133]	_	_
18-30	2309-2315	factor	abstract[128]|abstract[132]|abstract[133]	new[128]|new[132]|new[133]	_	_
18-31	2316-2317	,	_	_	_	_
18-32	2318-2332	angiopoietin-1	abstract	giv	coref	25-15[204_0]
18-33	2333-2334	(	_	_	_	_
18-34	2335-2339	from	_	_	_	_
18-35	2340-2343	the	abstract[136]	new[136]	_	_
18-36	2344-2356	angiopoietin	abstract|abstract[136]	new|new[136]	coref	19-20[147_0]
18-37	2357-2363	family	abstract[136]	new[136]	_	_
18-38	2364-2372	involved	abstract[136]	new[136]	_	_
18-39	2373-2375	in	abstract[136]	new[136]	_	_
18-40	2376-2388	pathological	abstract[136]|abstract[137]	new[136]|giv[137]	coref	19-12[145_137]
18-41	2389-2401	angiogenesis	abstract[136]|abstract[137]	new[136]|giv[137]	_	_
18-42	2402-2404	in	abstract[136]|abstract[137]	new[136]|giv[137]	_	_
18-43	2405-2412	chronic	abstract[136]|abstract[137]|abstract[139]	new[136]|giv[137]|giv[139]	coref	23-13[182_139]
18-44	2413-2418	liver	abstract[136]|abstract[137]|object|abstract[139]	new[136]|giv[137]|giv|giv[139]	coref	20-16
18-45	2419-2426	disease	abstract[136]|abstract[137]|abstract[139]	new[136]|giv[137]|giv[139]	_	_
18-46	2427-2428	)	_	_	_	_
18-47	2429-2431	in	_	_	_	_
18-48	2432-2436	LX-2	substance|animal[141]	giv|giv[141]	coref|coref	19-4[143_141]|26-10
18-49	2437-2442	cells	animal[141]	giv[141]	_	_
18-50	2443-2444	.	_	_	_	_

#Text=This suggests that fibrogenic cells such as HSC may participate in hepatic angiogenesis by secreting angiogenic factors such as angiopoietin 1 .
19-1	2445-2449	This	event	giv	_	_
19-2	2450-2458	suggests	_	_	_	_
19-3	2459-2463	that	_	_	_	_
19-4	2464-2474	fibrogenic	animal[143]	giv[143]	coref	22-31[176_143]
19-5	2475-2480	cells	animal[143]	giv[143]	_	_
19-6	2481-2485	such	animal[143]	giv[143]	_	_
19-7	2486-2488	as	animal[143]	giv[143]	_	_
19-8	2489-2492	HSC	animal[143]|abstract	giv[143]|giv	coref	21-3
19-9	2493-2496	may	_	_	_	_
19-10	2497-2508	participate	_	_	_	_
19-11	2509-2511	in	_	_	_	_
19-12	2512-2519	hepatic	abstract[145]	giv[145]	coref	20-13[151_145]
19-13	2520-2532	angiogenesis	abstract[145]	giv[145]	_	_
19-14	2533-2535	by	_	_	_	_
19-15	2536-2545	secreting	_	_	_	_
19-16	2546-2556	angiogenic	abstract[146]	new[146]	coref	21-24[165_146]
19-17	2557-2564	factors	abstract[146]	new[146]	_	_
19-18	2565-2569	such	abstract[146]	new[146]	_	_
19-19	2570-2572	as	abstract[146]	new[146]	_	_
19-20	2573-2585	angiopoietin	abstract[146]|abstract[147]	new[146]|giv[147]	_	_
19-21	2586-2587	1	abstract[146]|abstract[147]	new[146]|giv[147]	_	_
19-22	2588-2589	.	_	_	_	_

#Text=Indeed , the inhibition of HSC-secreted angiopietin-1 has shown to drastically reduce pathological angiogenesis and liver fibrosis induced in mice by either CCl4 or BDL .
20-1	2590-2596	Indeed	_	_	_	_
20-2	2597-2598	,	_	_	_	_
20-3	2599-2602	the	event[148]	new[148]	_	_
20-4	2603-2613	inhibition	event[148]	new[148]	_	_
20-5	2614-2616	of	event[148]	new[148]	_	_
20-6	2617-2629	HSC-secreted	event[148]|substance|abstract[150]	new[148]|new|new[150]	_	_
20-7	2630-2643	angiopietin-1	event[148]|abstract[150]	new[148]|new[150]	_	_
20-8	2644-2647	has	_	_	_	_
20-9	2648-2653	shown	_	_	_	_
20-10	2654-2656	to	_	_	_	_
20-11	2657-2668	drastically	_	_	_	_
20-12	2669-2675	reduce	_	_	_	_
20-13	2676-2688	pathological	abstract[151]|abstract[152]	giv[151]|giv[152]	coref	22-13[169_151]
20-14	2689-2701	angiogenesis	abstract[151]|abstract[152]	giv[151]|giv[152]	_	_
20-15	2702-2705	and	abstract[152]	giv[152]	_	_
20-16	2706-2711	liver	abstract[152]|object|object[154]	giv[152]|giv|giv[154]	coref|coref	21-19|28-27[235_154]
20-17	2712-2720	fibrosis	abstract[152]|object[154]	giv[152]|giv[154]	_	_
20-18	2721-2728	induced	abstract[152]|object[154]	giv[152]|giv[154]	_	_
20-19	2729-2731	in	abstract[152]|object[154]	giv[152]|giv[154]	_	_
20-20	2732-2736	mice	abstract[152]|object[154]|animal	giv[152]|giv[154]|new	_	_
20-21	2737-2739	by	abstract[152]|object[154]	giv[152]|giv[154]	_	_
20-22	2740-2746	either	abstract[152]|object[154]|abstract[156]	giv[152]|giv[154]|giv[156]	_	_
20-23	2747-2751	CCl4	abstract[152]|object[154]|abstract[156]	giv[152]|giv[154]|giv[156]	_	_
20-24	2752-2754	or	abstract[152]|object[154]	giv[152]|giv[154]	_	_
20-25	2755-2758	BDL	abstract[152]|object[154]|substance	giv[152]|giv[154]|new	_	_
20-26	2759-2760	.	_	_	_	_

#Text=Aside from HSC , hepatocytes have also been related to contribute to both phenomena , pathological angiogenesis and liver fibrosis , by releasing pro-angiogenic and pro-fibrogenic factors .
21-1	2761-2766	Aside	_	_	_	_
21-2	2767-2771	from	_	_	_	_
21-3	2772-2775	HSC	abstract	giv	coref	22-27
21-4	2776-2777	,	_	_	_	_
21-5	2778-2789	hepatocytes	animal	new	coref	22-29
21-6	2790-2794	have	_	_	_	_
21-7	2795-2799	also	_	_	_	_
21-8	2800-2804	been	_	_	_	_
21-9	2805-2812	related	_	_	_	_
21-10	2813-2815	to	_	_	_	_
21-11	2816-2826	contribute	_	_	_	_
21-12	2827-2829	to	_	_	_	_
21-13	2830-2834	both	abstract[160]	giv[160]	appos	21-16[161_160]
21-14	2835-2844	phenomena	abstract[160]	giv[160]	_	_
21-15	2845-2846	,	_	_	_	_
21-16	2847-2859	pathological	abstract[161]|abstract[162]	giv[161]|giv[162]	appos|appos	21-16[162_161]|21-19[164_162]
21-17	2860-2872	angiogenesis	abstract[161]|abstract[162]	giv[161]|giv[162]	_	_
21-18	2873-2876	and	abstract[162]	giv[162]	_	_
21-19	2877-2882	liver	abstract[162]|object|abstract[164]	giv[162]|giv|giv[164]	coref|coref	22-13[170_164]|22-17
21-20	2883-2891	fibrosis	abstract[162]|abstract[164]	giv[162]|giv[164]	_	_
21-21	2892-2893	,	_	_	_	_
21-22	2894-2896	by	_	_	_	_
21-23	2897-2906	releasing	_	_	_	_
21-24	2907-2921	pro-angiogenic	abstract[165]	giv[165]	coref	24-6[187_165]
21-25	2922-2925	and	abstract[165]	giv[165]	_	_
21-26	2926-2940	pro-fibrogenic	abstract[165]	giv[165]	_	_
21-27	2941-2948	factors	abstract[165]	giv[165]	_	_
21-28	2949-2950	.	_	_	_	_

#Text=There is a growing belief that local hypoxia is the link interconnecting both pathological angiogenesis and liver fibrogenesis , orchestrating the harmonic and coordinated activation of HSC , hepatocytes and other hepatic cells .
22-1	2951-2956	There	_	_	_	_
22-2	2957-2959	is	_	_	_	_
22-3	2960-2961	a	abstract[166]	new[166]	_	_
22-4	2962-2969	growing	abstract[166]	new[166]	_	_
22-5	2970-2976	belief	abstract[166]	new[166]	_	_
22-6	2977-2981	that	abstract[166]	new[166]	_	_
22-7	2982-2987	local	abstract[166]|abstract[167]|abstract[168]	new[166]|new[167]|new[168]	coref	24-12[189_167]
22-8	2988-2995	hypoxia	abstract[166]|abstract[167]|abstract[168]	new[166]|new[167]|new[168]	_	_
22-9	2996-2998	is	abstract[166]|abstract[168]	new[166]|new[168]	_	_
22-10	2999-3002	the	abstract[166]|abstract[168]	new[166]|new[168]	_	_
22-11	3003-3007	link	abstract[166]|abstract[168]	new[166]|new[168]	_	_
22-12	3008-3023	interconnecting	abstract[166]|abstract[168]	new[166]|new[168]	_	_
22-13	3024-3028	both	abstract[166]|abstract[168]|abstract[169]|abstract[170]	new[166]|new[168]|giv[169]|giv[170]	coref	24-30[0_169]
22-14	3029-3041	pathological	abstract[166]|abstract[168]|abstract[169]|abstract[170]	new[166]|new[168]|giv[169]|giv[170]	_	_
22-15	3042-3054	angiogenesis	abstract[166]|abstract[168]|abstract[169]|abstract[170]	new[166]|new[168]|giv[169]|giv[170]	_	_
22-16	3055-3058	and	abstract[166]|abstract[168]|abstract[170]	new[166]|new[168]|giv[170]	_	_
22-17	3059-3064	liver	abstract[166]|abstract[168]|abstract[170]|object|object[172]	new[166]|new[168]|giv[170]|giv|new[172]	coref	23-14
22-18	3065-3077	fibrogenesis	abstract[166]|abstract[168]|abstract[170]|object[172]	new[166]|new[168]|giv[170]|new[172]	_	_
22-19	3078-3079	,	abstract[166]|abstract[168]	new[166]|new[168]	_	_
22-20	3080-3093	orchestrating	abstract[166]|abstract[168]	new[166]|new[168]	_	_
22-21	3094-3097	the	abstract[166]|abstract[168]|event[173]	new[166]|new[168]|new[173]	coref	28-1[224_173]
22-22	3098-3106	harmonic	abstract[166]|abstract[168]|event[173]	new[166]|new[168]|new[173]	_	_
22-23	3107-3110	and	abstract[166]|abstract[168]|event[173]	new[166]|new[168]|new[173]	_	_
22-24	3111-3122	coordinated	abstract[166]|abstract[168]|event[173]	new[166]|new[168]|new[173]	_	_
22-25	3123-3133	activation	abstract[166]|abstract[168]|event[173]	new[166]|new[168]|new[173]	_	_
22-26	3134-3136	of	abstract[166]|abstract[168]|event[173]	new[166]|new[168]|new[173]	_	_
22-27	3137-3140	HSC	abstract[166]|abstract[168]|event[173]|abstract	new[166]|new[168]|new[173]|giv	coref	26-12
22-28	3141-3142	,	abstract[166]|abstract[168]|event[173]	new[166]|new[168]|new[173]	_	_
22-29	3143-3154	hepatocytes	abstract[166]|abstract[168]|event[173]|animal	new[166]|new[168]|new[173]|giv	coref	26-18
22-30	3155-3158	and	abstract[166]|abstract[168]|event[173]	new[166]|new[168]|new[173]	_	_
22-31	3159-3164	other	abstract[166]|abstract[168]|event[173]|animal[176]	new[166]|new[168]|new[173]|giv[176]	coref	27-18[222_176]
22-32	3165-3172	hepatic	abstract[166]|abstract[168]|event[173]|animal[176]	new[166]|new[168]|new[173]|giv[176]	_	_
22-33	3173-3178	cells	abstract[166]|abstract[168]|event[173]|animal[176]	new[166]|new[168]|new[173]|giv[176]	_	_
22-34	3179-3180	.	_	_	_	_

#Text=Detection of hypoxic areas is a common trait at any stage of chronic liver disease , expanding progressively from early injury to the development of cirrhosis .
23-1	3181-3190	Detection	abstract[177]	new[177]	coref	23-6[179_177]
23-2	3191-3193	of	abstract[177]	new[177]	_	_
23-3	3194-3201	hypoxic	abstract[177]|place[178]	new[177]|new[178]	_	_
23-4	3202-3207	areas	abstract[177]|place[178]	new[177]|new[178]	_	_
23-5	3208-3210	is	_	_	_	_
23-6	3211-3212	a	abstract[179]	giv[179]	_	_
23-7	3213-3219	common	abstract[179]	giv[179]	_	_
23-8	3220-3225	trait	abstract[179]	giv[179]	_	_
23-9	3226-3228	at	abstract[179]	giv[179]	_	_
23-10	3229-3232	any	abstract[179]|abstract[180]	giv[179]|new[180]	_	_
23-11	3233-3238	stage	abstract[179]|abstract[180]	giv[179]|new[180]	_	_
23-12	3239-3241	of	abstract[179]|abstract[180]	giv[179]|new[180]	_	_
23-13	3242-3249	chronic	abstract[179]|abstract[180]|abstract[182]	giv[179]|new[180]|giv[182]	coref	31-12[271_182]
23-14	3250-3255	liver	abstract[179]|abstract[180]|object|abstract[182]	giv[179]|new[180]|giv|giv[182]	coref	24-27
23-15	3256-3263	disease	abstract[179]|abstract[180]|abstract[182]	giv[179]|new[180]|giv[182]	_	_
23-16	3264-3265	,	abstract[179]	giv[179]	_	_
23-17	3266-3275	expanding	abstract[179]	giv[179]	_	_
23-18	3276-3289	progressively	abstract[179]	giv[179]	_	_
23-19	3290-3294	from	abstract[179]	giv[179]	_	_
23-20	3295-3300	early	abstract[179]|event[183]	giv[179]|new[183]	coref	29-40[0_183]
23-21	3301-3307	injury	abstract[179]|event[183]	giv[179]|new[183]	_	_
23-22	3308-3310	to	abstract[179]	giv[179]	_	_
23-23	3311-3314	the	abstract[179]|event[184]	giv[179]|new[184]	_	_
23-24	3315-3326	development	abstract[179]|event[184]	giv[179]|new[184]	_	_
23-25	3327-3329	of	abstract[179]|event[184]	giv[179]|new[184]	_	_
23-26	3330-3339	cirrhosis	abstract[179]|event[184]|abstract	giv[179]|new[184]|new	coref	30-29[260_0]
23-27	3340-3341	.	_	_	_	_

#Text=, Through the action of hypoxia-inducible factors ( HIF ) , hepatic hypoxia up-regulates the expression of a wide array of growth factors and mediators of liver repair and angiogenesis .
24-1	3342-3343	,	_	_	_	_
24-2	3344-3351	Through	_	_	_	_
24-3	3352-3355	the	event[186]	new[186]	_	_
24-4	3356-3362	action	event[186]	new[186]	_	_
24-5	3363-3365	of	event[186]	new[186]	_	_
24-6	3366-3383	hypoxia-inducible	event[186]|abstract[187]	new[186]|giv[187]	appos	24-9[0_187]
24-7	3384-3391	factors	event[186]|abstract[187]	new[186]|giv[187]	_	_
24-8	3392-3393	(	_	_	_	_
24-9	3394-3397	HIF	abstract	giv	coref	24-22[193_0]
24-10	3398-3399	)	_	_	_	_
24-11	3400-3401	,	_	_	_	_
24-12	3402-3409	hepatic	abstract[189]	giv[189]	coref	25-34[0_189]
24-13	3410-3417	hypoxia	abstract[189]	giv[189]	_	_
24-14	3418-3430	up-regulates	_	_	_	_
24-15	3431-3434	the	abstract[190]	new[190]	_	_
24-16	3435-3445	expression	abstract[190]	new[190]	_	_
24-17	3446-3448	of	abstract[190]	new[190]	_	_
24-18	3449-3450	a	abstract[190]|place[191]	new[190]|new[191]	_	_
24-19	3451-3455	wide	abstract[190]|place[191]	new[190]|new[191]	_	_
24-20	3456-3461	array	abstract[190]|place[191]	new[190]|new[191]	_	_
24-21	3462-3464	of	abstract[190]|place[191]	new[190]|new[191]	_	_
24-22	3465-3471	growth	abstract[190]|place[191]|abstract|abstract[193]|abstract[194]	new[190]|new[191]|new|giv[193]|giv[194]	coref|coref	24-22[194_193]|25-17
24-23	3472-3479	factors	abstract[190]|place[191]|abstract[193]|abstract[194]	new[190]|new[191]|giv[193]|giv[194]	_	_
24-24	3480-3483	and	abstract[190]|place[191]|abstract[194]	new[190]|new[191]|giv[194]	_	_
24-25	3484-3493	mediators	abstract[190]|place[191]|abstract[194]|person[195]	new[190]|new[191]|giv[194]|new[195]	_	_
24-26	3494-3496	of	abstract[190]|place[191]|abstract[194]|person[195]	new[190]|new[191]|giv[194]|new[195]	_	_
24-27	3497-3502	liver	abstract[190]|place[191]|abstract[194]|person[195]|object|event[197]	new[190]|new[191]|giv[194]|new[195]|giv|new[197]	coref	25-27[206_0]
24-28	3503-3509	repair	abstract[190]|place[191]|abstract[194]|person[195]|event[197]	new[190]|new[191]|giv[194]|new[195]|new[197]	_	_
24-29	3510-3513	and	abstract[190]|place[191]|abstract[194]|person[195]	new[190]|new[191]|giv[194]|new[195]	_	_
24-30	3514-3526	angiogenesis	abstract[190]|place[191]|abstract[194]|person[195]|abstract	new[190]|new[191]|giv[194]|new[195]|giv	coref	25-3[199_0]
24-31	3527-3528	.	_	_	_	_

#Text=However , pathological angiogenesis can be inefficient due to the immaturity and permeability of vascular endothelial growth factor ( VEGF)-induced new vessels and , consequently , the liver may be unable to reduce hypoxia .
25-1	3529-3536	However	_	_	_	_
25-2	3537-3538	,	_	_	_	_
25-3	3539-3551	pathological	abstract[199]	giv[199]	coref	28-20[0_199]
25-4	3552-3564	angiogenesis	abstract[199]	giv[199]	_	_
25-5	3565-3568	can	_	_	_	_
25-6	3569-3571	be	_	_	_	_
25-7	3572-3583	inefficient	_	_	_	_
25-8	3584-3587	due	_	_	_	_
25-9	3588-3590	to	_	_	_	_
25-10	3591-3594	the	abstract[200]	new[200]	_	_
25-11	3595-3605	immaturity	abstract[200]	new[200]	_	_
25-12	3606-3609	and	_	_	_	_
25-13	3610-3622	permeability	abstract[201]	new[201]	_	_
25-14	3623-3625	of	abstract[201]	new[201]	_	_
25-15	3626-3634	vascular	abstract[201]|abstract[204]|object[205]	new[201]|giv[204]|new[205]	_	_
25-16	3635-3646	endothelial	abstract[201]|abstract|abstract[204]|object[205]	new[201]|new|giv[204]|new[205]	_	_
25-17	3647-3653	growth	abstract[201]|abstract|abstract[204]|object[205]	new[201]|giv|giv[204]|new[205]	_	_
25-18	3654-3660	factor	abstract[201]|abstract[204]|object[205]	new[201]|giv[204]|new[205]	_	_
25-19	3661-3662	(	abstract[201]|object[205]	new[201]|new[205]	_	_
25-20	3663-3676	VEGF)-induced	abstract[201]|object[205]	new[201]|new[205]	_	_
25-21	3677-3680	new	abstract[201]|object[205]	new[201]|new[205]	_	_
25-22	3681-3688	vessels	abstract[201]|object[205]	new[201]|new[205]	_	_
25-23	3689-3692	and	_	_	_	_
25-24	3693-3694	,	_	_	_	_
25-25	3695-3707	consequently	_	_	_	_
25-26	3708-3709	,	_	_	_	_
25-27	3710-3713	the	object[206]	giv[206]	coref	28-29[0_206]
25-28	3714-3719	liver	object[206]	giv[206]	_	_
25-29	3720-3723	may	_	_	_	_
25-30	3724-3726	be	_	_	_	_
25-31	3727-3733	unable	_	_	_	_
25-32	3734-3736	to	_	_	_	_
25-33	3737-3743	reduce	_	_	_	_
25-34	3744-3751	hypoxia	abstract	giv	coref	26-1
25-35	3752-3753	.	_	_	_	_

#Text=Hypoxia up-regulates in vitro the expression of APJ in LX-2 ( HSC ) and in HepG2 ( hepatocytes ) .
26-1	3754-3761	Hypoxia	abstract	giv	coref	29-6
26-2	3762-3774	up-regulates	_	_	_	_
26-3	3775-3777	in	_	_	_	_
26-4	3778-3783	vitro	organization	giv	_	_
26-5	3784-3787	the	abstract[210]	new[210]	_	_
26-6	3788-3798	expression	abstract[210]	new[210]	_	_
26-7	3799-3801	of	abstract[210]	new[210]	_	_
26-8	3802-3805	APJ	abstract[210]|abstract	new[210]|giv	coref	27-16
26-9	3806-3808	in	abstract[210]	new[210]	_	_
26-10	3809-3813	LX-2	abstract[210]|substance	new[210]|giv	_	_
26-11	3814-3815	(	_	_	_	_
26-12	3816-3819	HSC	abstract	giv	coref	28-24
26-13	3820-3821	)	_	_	_	_
26-14	3822-3825	and	_	_	_	_
26-15	3826-3828	in	_	_	_	_
26-16	3829-3834	HepG2	substance	new	coref	27-18
26-17	3835-3836	(	_	_	_	_
26-18	3837-3848	hepatocytes	animal	giv	coref	29-17[242_0]
26-19	3849-3850	)	_	_	_	_
26-20	3851-3852	.	_	_	_	_

#Text=Interestingly , the pro-inflammatory and pro-fibrogenic agents TNF-α and AII also induce the expression of APJ in HepG2 cells .
27-1	3853-3866	Interestingly	_	_	_	_
27-2	3867-3868	,	_	_	_	_
27-3	3869-3872	the	substance[216]|abstract[217]	new[216]|new[217]	_	_
27-4	3873-3889	pro-inflammatory	substance[216]|abstract[217]	new[216]|new[217]	_	_
27-5	3890-3893	and	substance[216]|abstract[217]	new[216]|new[217]	_	_
27-6	3894-3908	pro-fibrogenic	substance[216]|abstract[217]	new[216]|new[217]	_	_
27-7	3909-3915	agents	substance[216]|abstract[217]	new[216]|new[217]	_	_
27-8	3916-3921	TNF-α	abstract[217]	new[217]	_	_
27-9	3922-3925	and	_	_	_	_
27-10	3926-3929	AII	abstract	giv	_	_
27-11	3930-3934	also	_	_	_	_
27-12	3935-3941	induce	_	_	_	_
27-13	3942-3945	the	abstract[219]	giv[219]	_	_
27-14	3946-3956	expression	abstract[219]	giv[219]	_	_
27-15	3957-3959	of	abstract[219]	giv[219]	_	_
27-16	3960-3963	APJ	abstract[219]|abstract	giv[219]|giv	coref	28-1
27-17	3964-3966	in	_	_	_	_
27-18	3967-3972	HepG2	substance|animal[222]	giv|giv[222]	coref|coref	28-4|28-4[226_222]
27-19	3973-3978	cells	animal[222]	giv[222]	_	_
27-20	3979-3980	.	_	_	_	_

#Text=APJ activation in HepG2 cells triggers the expression of VEGF-A and PDGF-β , factors that in turn may promote angiogenesis and activation of HSC and , consequently , liver fibrosis .
28-1	3981-3984	APJ	abstract|event[224]	giv|giv[224]	coref	29-13[240_0]
28-2	3985-3995	activation	event[224]	giv[224]	_	_
28-3	3996-3998	in	event[224]	giv[224]	_	_
28-4	3999-4004	HepG2	event[224]|substance|animal[226]	giv[224]|giv|giv[226]	_	_
28-5	4005-4010	cells	event[224]|animal[226]	giv[224]|giv[226]	_	_
28-6	4011-4019	triggers	_	_	_	_
28-7	4020-4023	the	abstract[227]	new[227]	_	_
28-8	4024-4034	expression	abstract[227]	new[227]	_	_
28-9	4035-4037	of	abstract[227]	new[227]	_	_
28-10	4038-4044	VEGF-A	abstract[227]|abstract	new[227]|new	_	_
28-11	4045-4048	and	abstract[227]	new[227]	_	_
28-12	4049-4055	PDGF-β	abstract[227]|abstract	new[227]|giv	appos	28-14[230_0]
28-13	4056-4057	,	_	_	_	_
28-14	4058-4065	factors	abstract[230]	giv[230]	coref	29-10[239_230]
28-15	4066-4070	that	abstract[230]	giv[230]	_	_
28-16	4071-4073	in	abstract[230]	giv[230]	_	_
28-17	4074-4078	turn	abstract[230]	giv[230]	_	_
28-18	4079-4082	may	abstract[230]	giv[230]	_	_
28-19	4083-4090	promote	abstract[230]	giv[230]	_	_
28-20	4091-4103	angiogenesis	abstract[230]|abstract	giv[230]|giv	_	_
28-21	4104-4107	and	abstract[230]	giv[230]	_	_
28-22	4108-4118	activation	abstract[230]|event[232]	giv[230]|new[232]	_	_
28-23	4119-4121	of	abstract[230]|event[232]	giv[230]|new[232]	_	_
28-24	4122-4125	HSC	abstract[230]|event[232]|abstract	giv[230]|new[232]|giv	coref	29-15
28-25	4126-4129	and	abstract[230]	giv[230]	_	_
28-26	4130-4131	,	abstract[230]	giv[230]	_	_
28-27	4132-4144	consequently	abstract[230]|object[235]	giv[230]|giv[235]	coref	29-38[0_235]
28-28	4145-4146	,	abstract[230]|object[235]	giv[230]|giv[235]	_	_
28-29	4147-4152	liver	abstract[230]|object|object[235]	giv[230]|giv|giv[235]	coref	30-29
28-30	4153-4161	fibrosis	abstract[230]|object[235]	giv[230]|giv[235]	_	_
28-31	4162-4163	.	_	_	_	_

#Text=According to these data , hypoxia , inflammation and pro-fibrogenic factors up-regulate APJ in HSC and hepatocytes , which can release different pro-angiogenic and pro-fibrogenic factors such as apelin ( from activated HSC ) together to perpetuate fibrosis while injury and these stimuli remain .
29-1	4164-4173	According	_	_	_	_
29-2	4174-4176	to	_	_	_	_
29-3	4177-4182	these	abstract[236]	giv[236]	_	_
29-4	4183-4187	data	abstract[236]	giv[236]	_	_
29-5	4188-4189	,	_	_	_	_
29-6	4190-4197	hypoxia	abstract	giv	_	_
29-7	4198-4199	,	_	_	_	_
29-8	4200-4212	inflammation	abstract	new	_	_
29-9	4213-4216	and	_	_	_	_
29-10	4217-4231	pro-fibrogenic	abstract[239]	giv[239]	coref	29-22[243_239]
29-11	4232-4239	factors	abstract[239]	giv[239]	_	_
29-12	4240-4251	up-regulate	_	_	_	_
29-13	4252-4255	APJ	abstract[240]	giv[240]	coref	30-4[0_240]
29-14	4256-4258	in	abstract[240]	giv[240]	_	_
29-15	4259-4262	HSC	abstract[240]|abstract	giv[240]|giv	coref	29-32[245_0]
29-16	4263-4266	and	abstract[240]	giv[240]	_	_
29-17	4267-4278	hepatocytes	abstract[240]|animal[242]	giv[240]|giv[242]	coref	30-9[0_242]
29-18	4279-4280	,	abstract[240]|animal[242]	giv[240]|giv[242]	_	_
29-19	4281-4286	which	abstract[240]|animal[242]	giv[240]|giv[242]	_	_
29-20	4287-4290	can	abstract[240]|animal[242]	giv[240]|giv[242]	_	_
29-21	4291-4298	release	abstract[240]|animal[242]	giv[240]|giv[242]	_	_
29-22	4299-4308	different	abstract[240]|animal[242]|abstract[243]	giv[240]|giv[242]|giv[243]	_	_
29-23	4309-4323	pro-angiogenic	abstract[240]|animal[242]|abstract[243]	giv[240]|giv[242]|giv[243]	_	_
29-24	4324-4327	and	abstract[240]|animal[242]|abstract[243]	giv[240]|giv[242]|giv[243]	_	_
29-25	4328-4342	pro-fibrogenic	abstract[240]|animal[242]|abstract[243]	giv[240]|giv[242]|giv[243]	_	_
29-26	4343-4350	factors	abstract[240]|animal[242]|abstract[243]	giv[240]|giv[242]|giv[243]	_	_
29-27	4351-4355	such	abstract[240]|animal[242]|abstract[243]	giv[240]|giv[242]|giv[243]	_	_
29-28	4356-4358	as	abstract[240]|animal[242]|abstract[243]	giv[240]|giv[242]|giv[243]	_	_
29-29	4359-4365	apelin	abstract[240]|animal[242]|abstract[243]|substance	giv[240]|giv[242]|giv[243]|giv	coref	30-14
29-30	4366-4367	(	abstract[240]|animal[242]	giv[240]|giv[242]	_	_
29-31	4368-4372	from	abstract[240]|animal[242]	giv[240]|giv[242]	_	_
29-32	4373-4382	activated	abstract[240]|animal[242]|abstract[245]	giv[240]|giv[242]|giv[245]	coref	30-11[0_245]
29-33	4383-4386	HSC	abstract[240]|animal[242]|abstract[245]	giv[240]|giv[242]|giv[245]	_	_
29-34	4387-4388	)	abstract[240]|animal[242]	giv[240]|giv[242]	_	_
29-35	4389-4397	together	abstract[240]|animal[242]	giv[240]|giv[242]	_	_
29-36	4398-4400	to	abstract[240]|animal[242]	giv[240]|giv[242]	_	_
29-37	4401-4411	perpetuate	abstract[240]|animal[242]	giv[240]|giv[242]	_	_
29-38	4412-4420	fibrosis	abstract[240]|animal[242]|object	giv[240]|giv[242]|giv	coref	32-37[283_0]
29-39	4421-4426	while	_	_	_	_
29-40	4427-4433	injury	event	giv	_	_
29-41	4434-4437	and	_	_	_	_
29-42	4438-4443	these	abstract[248]	new[248]	_	_
29-43	4444-4451	stimuli	abstract[248]	new[248]	_	_
29-44	4452-4458	remain	_	_	_	_
29-45	4459-4460	.	_	_	_	_

#Text=In vivo , APJ is upregulated preferentially in hepatocytes and HSC , while apelin levels are increased and localized in HSC in cirrhotic rats and in patients with liver cirrhosis caused by hepatitis C virus or ethanol .
30-1	4461-4463	In	_	_	_	_
30-2	4464-4468	vivo	abstract	new	_	_
30-3	4469-4470	,	_	_	_	_
30-4	4471-4474	APJ	abstract	giv	_	_
30-5	4475-4477	is	_	_	_	_
30-6	4478-4489	upregulated	_	_	_	_
30-7	4490-4504	preferentially	_	_	_	_
30-8	4505-4507	in	_	_	_	_
30-9	4508-4519	hepatocytes	animal|animal[252]	giv|giv[252]	coref	30-9[252_0]
30-10	4520-4523	and	animal[252]	giv[252]	_	_
30-11	4524-4527	HSC	animal[252]|abstract	giv[252]|giv	coref	30-21
30-12	4528-4529	,	_	_	_	_
30-13	4530-4535	while	_	_	_	_
30-14	4536-4542	apelin	substance|abstract[255]	giv|new[255]	coref|coref	31-2|31-1[265_255]
30-15	4543-4549	levels	abstract[255]	new[255]	_	_
30-16	4550-4553	are	_	_	_	_
30-17	4554-4563	increased	_	_	_	_
30-18	4564-4567	and	_	_	_	_
30-19	4568-4577	localized	_	_	_	_
30-20	4578-4580	in	_	_	_	_
30-21	4581-4584	HSC	abstract	giv	_	_
30-22	4585-4587	in	_	_	_	_
30-23	4588-4597	cirrhotic	animal[257]	giv[257]	_	_
30-24	4598-4602	rats	animal[257]	giv[257]	_	_
30-25	4603-4606	and	_	_	_	_
30-26	4607-4609	in	_	_	_	_
30-27	4610-4618	patients	person[258]	new[258]	_	_
30-28	4619-4623	with	person[258]	new[258]	_	_
30-29	4624-4629	liver	person[258]|object|abstract[260]	new[258]|giv|giv[260]	coref	31-5
30-30	4630-4639	cirrhosis	person[258]|abstract[260]	new[258]|giv[260]	_	_
30-31	4640-4646	caused	person[258]|abstract[260]	new[258]|giv[260]	_	_
30-32	4647-4649	by	person[258]|abstract[260]	new[258]|giv[260]	_	_
30-33	4650-4659	hepatitis	person[258]|abstract[260]|abstract[261]|abstract[262]	new[258]|giv[260]|new[261]|new[262]	_	_
30-34	4660-4661	C	person[258]|abstract[260]|abstract[261]|abstract[262]	new[258]|giv[260]|new[261]|new[262]	_	_
30-35	4662-4667	virus	person[258]|abstract[260]|abstract[262]	new[258]|giv[260]|new[262]	_	_
30-36	4668-4670	or	person[258]|abstract[260]	new[258]|giv[260]	_	_
30-37	4671-4678	ethanol	person[258]|abstract[260]|substance	new[258]|giv[260]|new	_	_
30-38	4679-4680	.	_	_	_	_

#Text=High apelin levels and liver damage have also been observed in human non-alcoholic fatty liver disease .
31-1	4681-4685	High	abstract[265]|abstract[266]	giv[265]|giv[266]	coref|coref	31-1[266_265]|32-7[274_266]
31-2	4686-4692	apelin	substance|abstract[265]|abstract[266]	giv|giv[265]|giv[266]	coref	32-8
31-3	4693-4699	levels	abstract[265]|abstract[266]	giv[265]|giv[266]	_	_
31-4	4700-4703	and	abstract[266]	giv[266]	_	_
31-5	4704-4709	liver	abstract[266]|object|abstract[268]	giv[266]|giv|new[268]	coref	31-14[270_0]
31-6	4710-4716	damage	abstract[266]|abstract[268]	giv[266]|new[268]	_	_
31-7	4717-4721	have	_	_	_	_
31-8	4722-4726	also	_	_	_	_
31-9	4727-4731	been	_	_	_	_
31-10	4732-4740	observed	_	_	_	_
31-11	4741-4743	in	_	_	_	_
31-12	4744-4749	human	abstract[271]	giv[271]	coref	32-18[277_271]
31-13	4750-4763	non-alcoholic	abstract[271]	giv[271]	_	_
31-14	4764-4769	fatty	animal|object[270]|abstract[271]	new|giv[270]|giv[271]	coref	32-19[0_270]
31-15	4770-4775	liver	object[270]|abstract[271]	giv[270]|giv[271]	_	_
31-16	4776-4783	disease	abstract[271]	giv[271]	_	_
31-17	4784-4785	.	_	_	_	_

#Text=A contemporary clinical investigation revealed that circulating apelin levels are associated with histological and hemodynamic features of chronic liver disease , but more clinical studies are needed to confirm the major relevance of apelin system in human liver fibrosis .
32-1	4786-4787	A	abstract[272]	new[272]	_	_
32-2	4788-4800	contemporary	abstract[272]	new[272]	_	_
32-3	4801-4809	clinical	abstract[272]	new[272]	_	_
32-4	4810-4823	investigation	abstract[272]	new[272]	_	_
32-5	4824-4832	revealed	_	_	_	_
32-6	4833-4837	that	_	_	_	_
32-7	4838-4849	circulating	abstract[274]	giv[274]	_	_
32-8	4850-4856	apelin	substance|abstract[274]	giv|giv[274]	coref	32-34
32-9	4857-4863	levels	abstract[274]	giv[274]	_	_
32-10	4864-4867	are	_	_	_	_
32-11	4868-4878	associated	_	_	_	_
32-12	4879-4883	with	_	_	_	_
32-13	4884-4896	histological	abstract[275]	new[275]	_	_
32-14	4897-4900	and	abstract[275]	new[275]	_	_
32-15	4901-4912	hemodynamic	abstract[275]	new[275]	_	_
32-16	4913-4921	features	abstract[275]	new[275]	_	_
32-17	4922-4924	of	abstract[275]	new[275]	_	_
32-18	4925-4932	chronic	abstract[275]|abstract[277]	new[275]|giv[277]	_	_
32-19	4933-4938	liver	abstract[275]|object|abstract[277]	new[275]|giv|giv[277]	coref	32-38
32-20	4939-4946	disease	abstract[275]|abstract[277]	new[275]|giv[277]	_	_
32-21	4947-4948	,	_	_	_	_
32-22	4949-4952	but	_	_	_	_
32-23	4953-4957	more	abstract[278]	new[278]	_	_
32-24	4958-4966	clinical	abstract[278]	new[278]	_	_
32-25	4967-4974	studies	abstract[278]	new[278]	_	_
32-26	4975-4978	are	_	_	_	_
32-27	4979-4985	needed	_	_	_	_
32-28	4986-4988	to	_	_	_	_
32-29	4989-4996	confirm	_	_	_	_
32-30	4997-5000	the	abstract[279]	new[279]	_	_
32-31	5001-5006	major	abstract[279]	new[279]	_	_
32-32	5007-5016	relevance	abstract[279]	new[279]	_	_
32-33	5017-5019	of	abstract[279]	new[279]	_	_
32-34	5020-5026	apelin	abstract[279]|substance|abstract[281]	new[279]|giv|new[281]	_	_
32-35	5027-5033	system	abstract[279]|abstract[281]	new[279]|new[281]	_	_
32-36	5034-5036	in	abstract[279]|abstract[281]	new[279]|new[281]	_	_
32-37	5037-5042	human	abstract[279]|abstract[281]|object[283]	new[279]|new[281]|giv[283]	_	_
32-38	5043-5048	liver	abstract[279]|abstract[281]|object|object[283]	new[279]|new[281]|giv|giv[283]	_	_
32-39	5049-5057	fibrosis	abstract[279]|abstract[281]|object[283]	new[279]|new[281]|giv[283]	_	_
32-40	5058-5059	.	_	_	_	_
